Overview

* Lyra reports Q3 2025 net loss of $6.0 mln, down from $11.9 mln last year

* Company plans new Phase 3 trial for LYR-210, aiming for NDA submission

* Cash reserves expected to fund operations into Q3 2026

Outlook

* Lyra plans new Phase 3 trial for LYR-210, targeting NDA submission

* Company anticipates cash reserves to fund operations until Q3 2026

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses due to completion of ENLIGHTEN 2 trial and workforce reduction

* G&A EXPENSES - Reduction in general and administrative expenses due to lower employee costs and operational savings

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $25,000

Collabor

ation

Revenue

Q3 EPS -$3.38

Q3 Net -$5.98

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Lyra Therapeutics Inc ( LYRA ) is $23.00, about 81.6% above its November 11 closing price of $4.24

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)